Clinical Trial Update: A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Efinopegdutide in participants with hepatic impairment and non-alcoholic steatohepatitis has completed and results are posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Disease
• Non-alcoholic Steatohepatitis

Drugs mentioned

• Efinopegdutide (efinopegdutide)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-alcoholic Steatohepatitis, Hepatic Impairment | Phase 1 | Status: COMPLETED | Results posted: 2025-10-22